Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MMMS latest filing. financial statement looks awesome. hang on folks. dont let the shorters screw you by scaring you with false info. The facts are the facts!! The shorters posts are all ambiguous and vague with no real factual info. Do your DD and you will see that if youre holding this stock right now you are extremely well positioned.
hold through imo. mmms on the nasdaq should be worth it
Hope so man, got way too much dough tied into this POS
expected. things should start to get interesting for the next couple of weeks. expecting the merger to be finalized early q3. june imo
It sure did, but back to 72 right before close. So today was just a head fake thanks to some freak dragging the price down. What a pity this has been as of lately
severe losses? most of us bought at .60 - 1.00 i don't think any longs have suffered "severe losses" and as long as they stay longs we all know even if you bought at 2.00, we're going to make a killing here. Based on the 1 for 1 merge with MMMS (4.00) a strong recommendation to hold this stock is advised. Giving bad advice to make money shorting here is a pretty cruddy thing to do. Rule #1 about ihub, most people here arent here to help you make money, theyre here to spread misinformation to make money OFF OF YOU. Be careful Ihubbers and do you DD before being tricked into making any costly mistakes.
Let's not resort to guessing or attempting to read between the lines here. : ) It is a 1 for 1 swap, with a price setting near $4, and, that is all that matters.
"We are fully prepared to submit the requisite initial listing application, and we believe the post-merger company will meet all criteria for initial listing on Nasdaq, except possibly the minimum bid price requirement of $4.00 per share. Notwithstanding, we have structured the capitalization of the post-merger company in a way that will optimize our chances of meeting or exceeding that requirement."
So I am wondering how they will structure this to meet the $4 minimum? Any thoughts, R/S...? If they can't get it to $4, will they not be on the Nasdaq at all?
Heres the nutshell. The merger is "definitive". That means it is happening. MMMS is 90% insider owned and once it's on the nasdaq Im sure there will be an offering. On that day, the chart will look like the side of a skyscraper. Short away so the rest of us can buy em cheap here, just dont get caught when the day comes because it will be a bloodbath.
Didnt JCB5 say he had a "large position" in CLRX? Obviously, thats not true, so what makes anyone think anything he says is? Let him try to drive it down a much as he can and make a few bucks a day, keep loading up and averaging down and then when CLRX turns into MMMS which is 90% insider owned. Let them make their first offering and watch see what it feels like to win the lottery. ;) GLTA
AND, I should know. I have been LONG in this kind of scenario hundreds of times. AND, I have gotten STINKY RICH off of OVER confident SHORT sellers!
; )
LONGS here are HOLDING! What that means is, there aren't ENOUGH shares available for sale. And, when LONGS sell, it will be at what they feel this is worth. POST merger price is expected to be $4+. What that means is:
SHORTS HERE ARE IN SERIOUS TROUBLE!
; )
SHORTS will have to COVER before any shortable shares come available!
ONLY 3,000 shares available to short!
That a bad recommendation.
There it IS folks! My CALL was RIGHT ON THE MONEY! Shorts coming on to say you should DUMP! CLASSIC! HOLD YOUR SHARES! SQUEEZE IS A COMIN! ROOOLF!
LOL Thanks, but, NO THANKS! LMMAO
Based on severe losses by longs, a recommendation is submitted to short until news verifies merger. the shareholders will vote and perhaps news by September IF merger will be finalized...the best to all in your trades of shorting or investing!
Short sellers HAVE TO COVER! LMMAO
It is going to be FUN to watch them try to cover, when there aren't enough shares available. That is when you wiil see it go $3+. I like the cheapies! Going make watching shorts cover, that much SWEETER.
You did sell out of all shares! Sounds good, this may go below 50 cents with short interest
it looks like the short interest remains very strong and may go below 50 cents and this is from over 2.50 when merger news was released
We'll see that $100 loss turn into a $600 gain.
Only lost $100 not too shabby
You can do it. If you have any positions that aren't outperforming S&P 500, I recommend closing them out to build up a cash reserve. Start buying this at the low point every day. Pretty soon, you will notice that your position has gone green. Keep doing this until you run out of stale cash. Then, HOLD. You will have done your part to keep the shares off of the street. And, you can be certain that the short sellers are going suffer because of it! ; )
It will be nice to have an endless amount of cash so you can keep buying at any point that you like
The other reason that I am in no rush for this to run back up is because I want the short sellers to continue dumping cheap shares. Since there will be a shortage of shares, the shorts won't be able to cover. They will be forced to pay a lot more than they sold at. In comes the board squeeling, I am looking forward to that. It will let me know that pain is being inflicted. And, it will signal that shorts are going to gap it back up. I will QUADruple my buys when that happens.
All in good time! : )
Make 'em shorts PAY to cover!
The benefit of incremental buying is that it takes shares off of the market. Without open orders, short sellers can't cover. That is part 2 of my plan to make bank here - take all the shares off the market.
I don't think this is the bottom its not in the oversold territory just yet but if goes to high .50s I will be a buyer..
To complement this strategy, I enter sale orders on all my shares. That locks them up so the broker can't loan them out.
In fact, that strategy will actually work for any long who wants to use it. If you have stale money, use it to keep you position +. If you run out of stale money, then, just hold here. Good things come to those who wait! ; )
My strategy here has been to buy at the lowest point every day. It is working to keep my position +. My incremental buys get bigger as the price falls.
No way to know for sure that it is the bottom. But, I can tell you where the top will be! : )
I'm sure you are hoping the best for all. LMAO
Amen
This is the bottom though
For sure
No need to rush this. Even if this never breaks past the current price, your current shares will bring $4 a piece, post merger. My suggestion is that you quietly load and forget about short sellers and any other item that distrays you from accumulating.
A lot of investors think that way. Although I understand, it can lead to missed oppurtunities. Like, the post merger valuation of a share here. It will be in the neighborhood of $4, and, we will get 1 share for every CLRX share. Even though that only represents 10% of MMMS, it will mean a DOUBLE in our current value. And, a 600% increase in share price from this level.
Come on rich, buy some shares at the bottom, lets drive her up
I think people like myself loss interest on here because the deal on the merger in my opinion is not that great.. I would of preferred being bought out by MMMS instead of merging.. I am glad I got out when they announced and cut down some of my loss even though it wasn't that much..
A rather small victory, to say the least.
I'm not worried about this. All in good time ; ) I am adding and holding.
Shorts have really taken control it appears with further price decline!
Hah, we went from 96 to 69 in a week. Congrats to shorts
nice to see someone gets it around here...
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1522
|
Created
|
04/04/13
|
Type
|
Free
|
Moderators |
CollabRx was co-founded in 2008 by a Silicon Valley tech pioneer/survivor of metastatic cancer and a Stanford professor with an expertise in biocomputing and Artificial Intelligence. They understood from personal experience that incredible amounts of information was available to patients and physicians over the “Cancer Internet”, but very little of it was truly personalized, actionable, and expert vetted. Consider there are over 500 new therapies in clinical development, more than 10,000 cancer-related clinical trials, and over 100,000 papers on cancer published each year, and it’s rapidly changing all the time––making it impossible for any one person to keep up.
CollabRx was started with the goal of bridging this knowledge gap and providing easily accessible information to patients and physicians by applying advanced Artificial Intelligence techniques in combination with actual clinical experts (i.e., “expert systems”) to filter the world’s knowledge in molecular medicine down to essential, highly curated content.
CollabRx is a data analytics company that uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on genomics-based medicine with specific insights from the nation’s top clinical experts.
That means we:
These activities result in products and services that support the unique needs of multiple healthcare markets.
Technology is revolutionizing how patients identify and act upon information that may be relevant for treating their particular condition or disease. Social networks are empowering patients, most notably those with cancer, and the Internet is making massive quantities of information accessible to everyone. Not only is it impossible for patients to keep up with the flood of information, there is also a notable lack of online resources that provide specific, actionable, and personalized therapy considerations that is both highly credible and current.
For patients, CollabRx provides actionable and highly credible information that can be shared with their physician in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. Patients currently interact with the CollabRx knowledge base via Web-based applications.
Our initial product for empowered patients (Therapy Finder™ – Professional) is a series of Web-based expert systemapplications currently available for melanoma, colorectal cancer, and lung cancer.
Market surveys indicate that while 90% of physicians desire to practice personalized medicine, only 10% feel adequately prepared to do so. The ever-growing quantity of genomic and other molecular data has thus far outpaced their ability to keep track of all the therapeutically relevant options that are available. As a result, a knowledge gap has developed between the desire and ability to apply molecular profiling to inform personalized treatment options.
For physicians, CollabRx provides sophisticated, yet intuitive decision support tools that enable rapid and accurate determination of relevant medical tests, therapies, and clinical trials that may have gone overlooked otherwise. By leveraging CollabRx’s customizable cloud-based expert systems, physicians have access to the most up-to-date, and credible molecular-based data to support optimal decision making and treatment planning.
This universal access to next generation healthcare boosts enrollment in clinical trials, increases in-house knowledge and expertise, fosters collaborative environments, and encourages patient-physician engagement.
CollabRx provides expert-backed, transparent, current, and peer-reviewed knowledge to physicians and patients to inform treatment plans that support optimal clinical outcomes and are as cost-efficient as possible.
Our cancer products and services highlight the primary molecular tests for physicians to consider that have therapeutic implications and that take into consideration the unique genetic profile of patient tumors. This targeted therapy approach to cancer treatment results in therapy plans that are more likely to be effective.
Thanks to technological advancements in next generation sequencing (NGS) that have reduced the time and cost to sequence entire genomes, the world is in the midst of a genetic information revolution. The ease and accuracy with which whole genomes can be sequenced is making genomics-based personalized medicine not only probable, but possible. When combined with patient medical records, the result is a dataset of unprecedented size and scope.
The sheer volume of data produced by NGS far exceeds the ability of individual physicians, drug developers and healthcare providers to stay up-to-date on its potential clinical relevance.
For NGS providers, CollabRx provides clinical interpretation of whole genome sequencing with an emphasis on what is actionable today based on the clinical strength of evidence linking observed mutations to therapy options, including drugs and clinical trials. As sequencing costs continue to fall, increased emphasis will be placed on the interpretation of sequencing data.
Biotechnology and pharmaceutical companies are increasingly developing drugs that target specific molecular abnormalities, particularly in oncology. CollabRx products and services provide awareness of approved drugs and diagnostics and those in clinical development.
CollabRx provides analytical services to pharma and biotech for business intelligence.
The number of molecular tests with therapeutic implications is rapidly increasing, particularly for cancer. Also, advances in next generation sequencing (NGS) platforms have made genetic sequencing less expensive, easier, and more accessible than ever before. As a result, disease knowledge and therapeutic intervention has the potential to be more specific and customized to individual patients if the right molecular tests are developed, interpreted, and applied. Until recently, there have been no highly scalable solutions to provide this service at the point of care for individual patients.
With the support of CollabRx products and services, labs can provide to ordering physicians clinically interpretive content, personalized for each patient, as part of the reporting process. This not only makes the results of molecular tests more actionable, but it also provides a rationale for why specific tests should be ordered in the first place––thus making it more useful for ordering physicians. CollabRx content is dynamically updated every two weeks, ensuring that the most up-to-date information is available to support clinical decisions.
With the amount of healthcare-related information now readily available on the Internet, it is often difficult to differentiate between what is accurate and clinically relevant, and what is not. CollabRx’s mission is to change the practice of medicine by making thought-leader medicine accessible to all––providing actionable medical and scientific content to drive informed treatment decision-making.
Designed with all healthcare participants in mind, CollabRx’s products and services are tailored to fit the needs of patients and healthcare professionals alike. By providing the industry with interactive and highly credible Web-based and mobile platforms and applications, users now have unlimited access to the most up-to-date information on drugs, diagnostics, and clinical trials associated with specific molecular profiles.
The CollabRx network of independent advisors is comprised of leading physicians, scientists, and researchers from the nation’s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.
CollabRx develops products that inform treatment planning by changing the way medical and scientific information is organized, interpreted and disseminated with the goal of providing high value knowledge in an easily accessible form.
CollabRx clinical products are point-of-care electronic resources to assist oncologists, other physicians and health care professionals, and cancer patients in creating a personalized treatment plan by leveraging the unique genetic profiles of a given patient’s tumor.
The CancerRx™ app is a mobile clinical decision support resource designed to help physicians and their patients navigate the complex landscape of oncology therapeutic options. It currently offers expert-vetted guidance of treatment options (i.e., drugs, tumor genetic tests) for lung cancer, melanoma, metastatic breast cancer and colorectal cancer based on tumor genetic profiles, stage, and histology in addition to other important clinical parameters such as treatment history. In addition to treatment options based on the current standard of care, CancerRx helps physicians and patients identify the most relevant clinical trials of investigational therapies, and provides summaries and links to clinical findings published in top tier medical journals and presented at national conferences for oncologists and other physicians involved in the care of cancer patients. A special feature of CancerRx is a daily oncology newsfeed from MedPage Today, all with real-time over the air updates.
All knowledge is developed in close collaboration with CollabRx’s expert advisory network, which is composed of over 75 leading physicians, scientists, and researchers from the nation’s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.
Therapy Finders are a series of Web-based expert system applications (“apps”) that enable physicians and their patients to learn which tests should be considered for tumor molecular analysis and how to use the results of those tests in evaluating therapy options including approved and investigational drugs and clinical trials. The rationale for knowledge delivered via CollabRx Therapy Finders is transparent, associated with peer-reviewed publications, and generated by CollabRx scientific staff in collaboration with editorial boards of leading clinical practitioners.
Therapy Finder apps are freely accessible, provided for specific cancer types, and delivered in a form optimized for health care professionals (Professional version) and patients and caregivers (Patient version). The Therapy Finder – Professional version is currently available for melanoma, colorectal cancer, and lung cancer. Other cancer types and Patient versions are in development. Also in development is an oncology-specific mobile app that will incorporate the Therapy Finders and ultimately serve as a comprehensive point of care resource for physicians and patients to obtain highly credible, expert-vetted and dynamically updated information to guide cancer treatment planning. Read the press release.
CollabRx is developing Web-based resources and apps to provide expert-vetted interpretation of molecular cancer panels, including clinical next-generation sequencing of tumors, in collaboration with our Pan Cancer molecular oncology Editorial Board.
The CollabRx GVA Service provides for a fully automated and scalable medical informatics solution to inform patient treatment planning by seamlessly pairing the results of genetic sequencing tests (generated on any platform) with clinically actionable and dynamically updated knowledge (provided by CollabRx in the form of interpretive reports). Knowledge contained within GVA reports includes the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and clinical trials. This content leverages the CollabRx semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s knowledge base with the latest medical and scientific data available in the public domain. This knowledge is further contextualized in collaboration with CollabRx’s large and growing formal network of over 75 leading clinical practitioners in the U.S. and Europe.
Disease and Biomarker Coverage*
The GVA Service is currently available in oncology for all adult solid tumor types to support the clinical interpretation of tests to elucidate tumor mutation profiles generated on any testing platform, including next generation sequencing (NGS) devices. Tumor genetic alterations currently interpreted by the GVA Service include single base pair substitutions (missense and nonsense mutations) and nucleotide insertions and deletions (frameshift mutations). Support for other types of tumors (e.g., hematological malignancies) and genetic alterations (e.g., gene copy number variation (CNV), etc.) are in late stage development. There are hundreds of biomarkers and thousands of genetic alterations, drugs, and annotated clinical trials currently in the GVA knowledge base, all of which are linked to summary level information presented in a cancer type specific manner. This information directly supports clinical decision-making and includes expert-vetted statements describing clinical impact, therapeutic strategies, and potential drugs and clinical trials to consider during cancer treatment planning. Clinical guidelines, citations from the peer-reviewed medical and scientific literature, and other publicly available sources of information are provided in support of all information contained in GVA reports.
*Download an overview of the GVA Service. Detailed specifications and sample GVA reports are available upon request.
Delivery Model
Click here to see partner laboratories or contact us to to learn more about the GVA Service or other CollabRx products and services.
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology.
The company’s patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible materials surfaces. This unique development may be utilized for a variety of additional medical applications requiring low cost therapeutic ultrasound qualities.
The company’s PainShield™ MD product has gained CE Mark certification and FDA clearance while the UroShield™ is currently CE mark certified.
NanoVibronix Inc. is located in Long Island, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.
http://www.collabrx.com/investors/recent-communications/
http://www.collabrx.com/collabrx-and-medytox-solutions-sign-definitive-merger-agreement/
Contact us regarding investor information.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |